Background Nirmatrelvir–ritonavir has been authorized for emergency use by many
countries for the treatment of coronavirus disease 2019 (Covid-19). However, the supply …

Background Nirmatrelvir is an orally administered severe acute respiratory syndrome
coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in …

Nirmatrelvir/ritonavir (Paxlovid™) is an effective and safe antiviral drug that inhibits the main
protease (Mpro), 3CL protease, of SARS-CoV-2. A reduction in COVID-19-related …

Coronavirus disease 2019 (COVID‐19) is a continued leading cause of hospitalization and
death. Safe, efficacious COVID‐19 antivirals are needed urgently. Nirmatrelvir (PF …

This network meta-analysis compared the clinical efficacy and safety of anti-viral agents for
the prevention of disease progression among non-hospitalized patients with COVID-19 …

Background Oral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …

At a crucial time with rapid spread of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) Omicron variant globally, the United States Food and Drug Administration …

Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-
19 antiviral treatments, but their antiviral activities in patients have not been compared …

Introduction Different antivirals are available for the treatment of outpatients with COVID-19.
Our aim was to describe a real-world experience of outpatient management of COVID-19 …

At present, there are some differences in the research results of nirmatrelvir–ritonavir
compared with other antiviral drugs for the treatment of COVID‐19 patients. We aimed to …